Sector News

Inositec names ex-Roche, Novartis staffer as CMO

January 19, 2018
Life sciences

Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.

Zurich, Switzerland-based Inositec hired van Alphen away from Roche, where he led the operational excellence team. Earlier in his career, van Alphen worked as CMO of Vifor Pharma and headed up European medical affairs at Novartis. The Novartis role also gave van Alphen responsibility for leading the company’s clinical operations team in the Netherlands. Van Alphen will now use this experience to guide Inositec into and through the clinic.

Inositec spun out of ETH Zurich late in 2015 to develop drugs based on inositol hexaphosphate. The biotech has a platform capable of replacing phosphate groups on the molecule with a view to giving them druglike properties. Inositec sees the small molecules treating a range of conditions. Vascular calcification is top of its hit list.

The small molecules advancing down the pipeline at Inositec are designed to inhibit pathological crystallization in soft tissues and thereby prevent the stiffening and blockage of arteries. If the R&D strategy goes according to plan, the drugs will have these effects regardless of the root cause of the vascular calcification, making them suitable for use in all calcification-dependent cardiovascular diseases.

Inositec is some way from clinically validating its belief in this mechanism. But with van Alphen in the CMO seat, it has taken another step toward generating supportive data.

“Dr. van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” Inositec CEO Mattias Ivarsson, Ph.D., said in a statement.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach